{"Clinical Trial ID": "NCT00038103", "Intervention": ["INTERVENTION 1:", "- Exemestane (Exemestane alone)", "\u00b7 oral dose of exemestane taken with food (25 mg tablets once daily)", "INTERVENTION 2:", "- Combination (exemestane + celecoxib)", "\u2022 Oral dose to be taken with food (25 mg of exemestane tablet once daily; celecoxib 2 x 200 mg tablets twice daily)"], "Eligibility": ["Incorporation criteria:", "A postmenopausal patient with histologically or cytologically confirmed breast cancer who has progressed on Tamoxifene.", "\u2022 Advanced disease: patients with advanced breast carcinoma whose disease progression has progressed/released after more than 8 weeks of treatment with Tamoxifen for advanced disease; or who have progressed during Tamoxifen adjuvant for at least 6 or 12 months depending on the recipient's condition; or who have progressed within 12 months of completion of adjuvant treatment with Tamoxifen.", "At least one measurable injury", "- Exclusion criteria:", "More than one prior chemotherapy and/or more than one hormone therapy for an advanced disease.", "- Previous hormone therapy for advanced disease other than tamoxifen.", "Myocardial infarction in the previous 6 months"], "Results": ["Performance measures:", "Number of subjects with clinical benefit", "The clinical benefit was based on objective tumour evaluations performed using the one-dimensional response criteria assessment system (RECIST). Includes subjects with a complete response (CR), partial response (PR) and long-term disease stabilization (SD) for at least 24 weeks.", "Timeline: Baseline, week 8, 16, 24 and every 12 weeks beyond 24 weeks until week 108 and every 24 weeks thereafter until 9 months after last subject visit (LSLV)", "Results 1:", "Title of the arm/group: Exemestane (Exemestane alone)", "Description of the arm/group: oral dose of exemestane taken with food (25 mg tablet once daily)", "Total number of participants analysed: 49", "Type of measurement: Number", "Unit of measurement: participants 24", "Results 2:", "- Arm/group title: Combination (Exemestane + Celecoxib)", "Description of the arm/group: oral doses to be taken with food (25 mg of exemestane tablet once daily; celecoxib 2 x 200 mg tablets twice daily)", "Total number of participants analysed: 51", "Type of measurement: Number", "Unit of measurement: participants 24"], "Adverse Events": ["Undesirable Events 1:", "Total: 9", "Congestive heart failure 0/53 (0.00 %)", "Ascites 1/53 (1.89%)", "Nausea 1/53 (1.89%)", "Vomiting 2/53 (3.77 per cent)", "Intestinal obstruction 1/53 (1.89%)", "Diarrhoea 0/53 (0.00 %)", "Pain 1/53 (1.89%)", "Deaths 1/53 (1.89 %)", "General deterioration of physical health 1/53 (1.89 per cent)", "Wait Disturbance 1/53 (1.89%)", "Asthenia 2/53 (3.77%)", "- Fatigue 0/53 (0.00 %)", "Adverse Events 2:", "Total: 14", "Congestive heart failure 1/56 (1.79%)", "Ascites 0/56 (0.00 %)", "Nausea 0/56 (0.00 %)", "Vomiting 0/56 (0.00 %)", "Intestinal obstruction 0/56 (0.00 %)", "Diarrhoea 1/56 (1.79%)", "Pain 1/56 (1.79 per cent)", "Deaths 1/56 (1.79 %)", "General deterioration of physical health 1/56 (1.79 per cent)", "Wait Disturbance 1/56 (1.79 per cent)", "Asthenia 0/56 (0.00 %)", "Fatigue 1/56 (1.79 per cent)"]}